Search

Taking 7A52 aluminum alloy as the object, the preparation process optimization and corrosion resistance research of micro-arc oxidation ceramic layer were carried out.The response surface method was used to design the micro-arc oxidation test, and the effects of voltage, frequency, and graphene additive concentration on the thickness and porosity of the micro-arc oxidation ceramic layer were studied in the silicate electrolyte system.Furthermore, the Quadratic model was used to fit the data, the Criteria was used to conduct predictive analysis and perform experimental validation of predictive parameters and response values.The response surface analysis showed that when the conditions were 465.52 V of predicted voltage, 102.66 Hz of frequency and 0.38 g/L of graphene concentration, it possessed 9.992 61% of the optimal porosity and 15.427 7 μm of the optimal ceramic layer thickness.Experiments with the above conditions showed that the measured porosity of as-prepared layer was 9.6%, and the thickness was 12.76 μm.Moreover, the electrochemical tests on the micro-arc oxidation ceramic layer prepared under this conditions indicated that the corrosion potential increased significantly, and the corrosion current decreased, which inferred that the layer had good corrosion resistance.

Micro - arc oxidation technology of aluminum alloy is an environmental friendly and efficient surface treatment method of aluminum alloy in the 21st century. After years of theoretical accumulation and engineering practice, various kinds of additives were widely used in the industry to improve the performance of micro - arc oxidation coating. In this paper, the research status of various additives in micro - arc oxidation of aluminum alloy was introduced from three categories of soluble salt additive, nano particle additive and composite additive, their action mechanism was also discussed.

299 samples of highland barley were collected from Gansu, Tibet, Qinghai and Sichuan provinces, 143 mycotoxins were analysed by HPLC-MS/MS. The results showed that 13 mycotoxins in the samples from every province were not beyond the standard, just only T-2 Toxin and Zearalenone found. The detection rate of T-2 toxin in some areas of Qinghai was 49.26%; The detection rates of T-2 toxin, and zearalenone (ZEN) in some areas of Sichuan were 13.89% and 8.33% respectively; The detection rate of T-2 toxin in Gansu Province was 16.67%, which was not over the standard; The detection rate of ZEN in Tibet was 3.09%. According to the analysis data, the detection rates of T-2 toxin and ZEN were significantly different under different harvest methods and storage conditions (P < 0.05).

The rapidly evolving landscape of biomarkers for colorectal cancer (CRC) necessitates an integrative, updated repository. In response, we constructed the Colorectal Cancer Biomarker Database (CBD), which collected and displayed the curated biomedicine information for 870 CRC biomarkers in the previous study. Building on CBD, we have now developed CBD2, which includes information on 1569 newly reported biomarkers derived from different biological sources (DNA, RNA, protein, and others) and clinical applications (diagnosis, treatment, and prognosis). CBD2 also incorporates information on nonbiomarkers that have been identified as unsuitable for use as biomarkers in CRC. A key new feature of CBD2 is its network analysis function, by which users can investigate the visible and topological network between biomarkers and identify their relevant pathways. CBD2 also allows users to query a series of chemicals, drug combinations, or multiple targets, to enable multidrug, multitarget, multipathway analyses, toward facilitating the design of polypharmacological treatments for CRC. CBD2 is freely available at http://www.eyeseeworld.com/cbd. Highlights: CBD2 integrates biomarkers derived from diverse biological sources and clinical applications, employing a standardized approach for annotation and classification.CBD2 facilitates precision medicine in colorectal cancer by providing abundant data, including drug–target information and visualized network analysis functions.With its user‐friendly interface, CBD2 aids in the identification and development of biomarkers for colorectal cancer. [ABSTRACT FROM AUTHOR]

Due to the heterogeneity of colon cancer, surgery, chemotherapy, and radiation are ineffective in all cases. The genomic profile and biomarkers associated with the process are considered in personalized medicine, along with the patient's personal history. It is based on the response of the targeted therapies to specific genetic variations. The patient's genetic transcriptomic and epigenetic features are evaluated, and the best therapeutic approach and diagnostic testing are identified through personalized medicine. This review aims to summarize all the necessary, updated information on colon cancer related to personalized medicine. Personalized medicine is gaining prominence as generalized treatments are finding it challenging to contain colon cancer cases which currently rank fourth among global cancer incidence while being the fifth largest in total death cases worldwide. In personalized therapy, patients are grouped into specific categories, and the best therapeutic approach is chosen based on evaluating their molecular features. Various personalized strategies are currently being explored in the treatment of colon cancer involving immunotherapy, phytochemicals, and other biomarker-specific targeted therapies. However, significant challenges must be overcome to integrate personalized medicine into healthcare systems completely. We look at the various signaling pathways and genetic and epigenetic alterations associated with colon cancer to understand and identify biomarkers useful in targeted therapy. The current personalized therapies available in colon cancer treatment and the strategies being explored to improve the existing methods are discussed. This review highlights the advantages and limitations of personalized medicine in colon cancer therapy. The current scenario of personalized medicine in developed countries and the challenges faced in middle- and low-income countries are also summarized. Finally, we discuss the future perspectives of personalized medicine in colon cancer and how it could be integrated into the healthcare systems. [ABSTRACT FROM AUTHOR]